Medtronic announces navablate study results released in late-breaking podium presentation at european respiratory society international congress 2021

Results demonstrate feasibility of bronchoscopic microwave ablation for certain patients with malignant lung nodules dublin, sept. 7, 2021 /prnewswire/ -- medtronic plc (nyse:mdt), the global leader in medical technology, today announced new clinical data from the navablate study, which highlights the much anticipated safety and performance results on microwave ablation used bronchoscopically with the emprint™ ablation catheter kit with thermosphere™ technology in conjunction with the medtronic electromagnetic navigation bronchoscopy system.
MDT Ratings Summary
MDT Quant Ranking